Xenoestrogen action in breast cancer: Impact on ER-dependent transcription and mitogenesis

Breast Cancer Research and Treatment

Volumn 96, Issue 3, 2006, Pages 279-292

  Hess Wilson, J K ^a   Boldison, J ^a   Weaver, K E ^a   Knudsen, K E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bisphenol A; Breast cancer; Co activators; Coumestrol; ER D351Y; Estrogen receptor; Xenoestrogens

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BETA GALACTOSIDASE; COUMESTROL; CYCLIN D1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; TAMOXIFEN; XENOBIOTIC AGENT;

AGONIST; ALLELE; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DEPLETION; ESTROGEN ACTIVITY; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; MITOGENESIS; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COUMESTROL; ESTRADIOL; FEMALE; HUMANS; PHENOLS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 33645710947     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9082-y     Document Type: Article

References (95)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54(1): 8-29, 2004
2. Lacey JV Jr., Devesa SS, Brinton LA: Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39(2-3): 82-8, 2002
3. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer. Lancet Oncol 2(3): 133-40, 2001
4. Coyle YM: The effect of environment on breast cancer risk. Breast Cancer Res Treat 84(3): 273-88, 2004
5. Tilson-Mallett N, Santner SJ, Feil PD, Santen RJ: Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 57(6): 1125-8, 1983
6. Huff J, Boyd J, Barrett JC: Hormonal carcinogenesis and environmental influences: background and overview. Prog Clin Biol Res 394: 3-23, 1996
7. Davis DL, Pongsiri MJ, Wolff M: Recent developments on the avoidable causes of breast cancer. Ann N Y Acad Sci 837: 513-23, 1997
8. Platet N, Cathiard AM, Gleizes M, Garcia M: Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1): 55-67, 2004
9. McDonnell DP: The molecular determinants of estrogen receptor pharmacology. Maturitas 48(Suppl 1): 7-12, 2004
10. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295(5564): 2465-8, 2002
11. Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A, Russo IH: Biological and molecular basis of human breast cancer. Front Biosci 3: D944-60, 1998
12. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2(10): 1102-9, 1984
13. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15(2 Suppl 1): 20-5, 1988
14. Jordan VC: The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer 16(3): 129-76, 1992
15. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652): 753-8, 1997
16. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95(7): 927-37, 1998
17. Sainsbury R: Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer 90(9): 1733-9, 2004
18. Hayes, DF, Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst 96(12) (2004). 895-7
19. Arora A, Potter JF: Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J Am Geriatr Soc 52(4): 611-6, 2004
20. Herynk, M.H. and SA, Fuqua, Estrogen Receptor Mutations in Human Disease. Endocr Rev (2004)
21. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC: A hypersensitive estrogen receptor-alpha mutation in pre-malignant breast lesions. Cancer Res 60(15): 4026-9, 2000
22. Fuqua SA, Chamness GC, McGuire WL: Estrogen receptor mutations in breast cancer. J Cell Biochem 51(2): 135-9, 1993
23. Sommer S, Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol 11(5): 339-52, 2001
24. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA: Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36(48): 14897-905, 1997
25. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS: Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10(11): 1388-98, 1996
26. Skafar DF: Formation of a powerful capping motif corresponding to start of "helix 12" in agonist-bound estrogen receptor-alpha contributes to increased constitutive activity of the protein. Cell Biochem Biophys 33(1): 53-62, 2000
27. Anghel SI, Perly VG, Melancon A, Barsalou S, Chagnon A, Rosenauer WH, Miller Jr., Mader S: Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. J Biol Chem 275(27): 20867-72, 2000
28. Levenson AS, Catherino WH, Jordan VC: Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60(5-6): 261-8, 1997
29. Catherino WH, Wolf DM, Jordan VC: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9(8): 1053-63, 1995
30. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF: Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 78(2): 193-204, 2003
31. Barnes DM, Gillett CE: Cyclin D1 in breast cancer. Breast Cancer Res Treat 52(1-3): 1-15, 1998
32. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17(9): 5338-47, 1997
33. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88(3): 405-15, 1997
34. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12(22): 3488-98, 1998
35. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW: The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273(20): 12101-8, 1998
36. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57(3): 353-61, 1994
37. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL: Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3(6): 849-54, 1997
38. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients.. Int J Cancer 98(3): 415-8, 2002
39. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS: Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53(2): 74-80, 2003
40. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69(2): 92-9, 1996
41. Berns EM, van Staveren IL, Klijn JG, Foekens JA: Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 48(1): 87-92, 1998
42. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H: Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 6(2): 512-8, 2000
43. Zhang H, Yi X, Sun X, Yin N, Shi B, Wu H, Wang D, Wu G, Shang Y: Differential gene regulation by the SRC family of co-activators. Genes Dev 18(14): 1753-65, 2004
44. Adlercreutz H: Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol 83(1-5): 113-8, 2002
45. Adlercreutz H: Phyto-oestrogens and cancer. Lancet Oncol 3(6): 364-73, 2002
46. Bentrem D, Fox JE, Pearce ST, Liu H, Pappas S, Kupfer D, Zapf JW, Jordan VC: Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res 63(21): 7490-6, 2003
47. McLachlan JA: Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 22(3): 319-41, 2001
48. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D: Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology 132(6): 2279-86, 1993
49. Inoue K, Kato K, Yoshimura Y, Makino T, Nakazawa H: Determination of bisphenol A in human serum by high-performance liquid chromatography with multi-electrode electrochemical detection. J Chromatogr B Biomed Sci Appl 749(1): 17-23, 2000
50. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ: Phytoestrogens: recent developments. Planta Med 69(7): 589-99, 2003
51. Olsen CM, Meussen-Elholm ET, Samuelsen M, Holme JA, Hongslo JK: Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxybiphenyl and 4,4′-dihydroxybiphenyl on oestrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7. Pharmacol Toxicol 92(4): 180-8, 2003
52. Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, Inoue S, Muramatsu M, Masamune Y: Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol Pharm Bull 25(1): 48-52, 2002
53. Schafer WR, Zahradnik HP: Organochlorine compounds and xenoestrogens in human endometrium. Adv Exp Med Biol 444: 5-8, 1998
54. Routledge EJ, White R, Parker MG, Sumpter JP: Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J Biol Chem 275(46): 35986-93, 2000
55. Onate SA, Tsai SY, Tsai MJ, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270(5240): 1354-7, 1995
56. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10(10): 1167-77, 1996
57. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264(5164): 1455-8, 1994
58. Petre CE, Wetherill YB, Danielsen M, Knudsen KE: Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 277(3): 2207-15, 2002
59. Chen C, Okayama H: High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7(8): 2745-52, 1987
60. Engel LW, Young NA: Human breast carcinoma cells in continuous culture: a review. Cancer Res 38(11 Pt 2): 4327-39, 1978
61. Kasid A, Lippman ME, Papageorge AG, Lowy DR, Gelmann EP: Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 228(4700): 725-8, 1985
62. Prall OW, Rogan EM, Sutherland RL: Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 65(1-6): 169-74, 1998
63. Takeuchi T, Tsutsumi O: Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophys Res Commun 291(1): 76-8, 2002
64. Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S: Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 124(6): 825-32, 1994
65. Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S: Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 125(9): 2307-15, 1995
66. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K: Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 142(2): 251-9, 1994
67. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS: Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect 111(8): 994-1006, 2003
68. Levenson AS, Jordan VC: MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57(15): 3071-8, 1997
69. Hall JM, McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140(12): 5566-78, 1999
70. Lazennec G, Ediger TR, Petz LN, Nardulli AM, Katzenellenbogen BS: Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endocrinol 11(9): 1375-86, 1997
71. White R, Sjoberg M, Kalkhoven E, Parker MG: Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. Embo J 16(6): 1427-35, 1997
72. Levenson AS, Svoboda KM, Kwaan HC, Jordan VC: Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Lett 125(1-2): 215-20, 1998
73. Tai H, Kubota N, Kato S: Involvement of nuclear receptor co-activator SRC-1 in estrogen-dependent cell growth of MCF-7 cells. Biochem Biophys Res Commun 267(1): 311-6, 2000
74. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. Embo J 15(14): 3667-75, 1996
75. Fu M, Wang C, Li Z, Sakamaki T, Pestell, RG: Minireview: Cyclin D1: Normal and Abnormal Functions. Endocrinology (2004)
76. Zoeller RT, Bansal R, Parris, C: Bisphenol-A, an Environmental Contaminant that Acts as a Thyroid Hormone Receptor Antagonist In Vitro, Increases Serum Thyroxine and Alters RC3/Neu-rogranin Expression in the Developing Rat Brain. Endocrinology (2004)
77. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE: Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 350(9070): 23-7, 1997
78. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A: Bioavailability of phyto-oestrogens. Br J Nutr 89(Suppl 1): S45-58, 2003
79. Zubik L, Meydani M: Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am J Clin Nutr 77(6): 1459-65, 2003
80. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139(10): 4252-63, 1998
81. Rivas A, Lacroix M, Olea-Serrano F, Laios I, Leclercq G, Olea N: Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 82(1): 45-53, 2002
82. Vivacqua A, Recchia AG, Fasanella G, Gabriele S, Carpino A, Rago V, Di Gioia ML, Leggio A, Bonofiglio D, Liguori A, Maggiolini M: The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine 22(3): 275-84, 2003
83. Schafer TE, Lapp CA, Hanes CM, Lewis JB, Wataha JC, Schuster GS: Estrogenicity of bisphenol A and bisphenol A dimethacrylate in vitro. J Biomed Mater Res 45(3): 192-7, 1999
84. Olea N, Pulgar R, Perez P, Olea-Serrano F, Rivas A, Novillo-Fertrell A, Pedraza V, Soto AM, Sonnenschein C: Estrogenicity of resin-based composites and sealants used in dentistry. Environ Health Perspect 104(3): 298-305, 1996
85. Schmitt E, Dekant W, Stopper H: Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 15(4-5): 433-9, 2001
86. Forbes JF: The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24(1 Suppl 1): S1-20-S135, 1997
87. Forbes JF: The control of breast cancer: the role of tamoxifen. Semin Oncol 24(1 Suppl 1): S1-5-S119, 1997
88. Feigelson HS, Henderson BE: Estrogens and breast cancer. Carcinogenesis 17(11): 2279-84, 1996
89. Wiseman LR, Adkins JC: Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 13(4): 321-32, 1998
90. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22): 3758-67, 2000
91. Ingle JN, Suman VJ: Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. J Steroid Biochem Mol Biol 86(3-5): 313-9, 2003
92. Buzdar AU, Hortobagyi G: Update on endocrine therapy for breast cancer. Clin Cancer Res 4(3): 527-34, 1998
93. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16(2): 453-61, 1998
94. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study. Clin Breast Cancer 1(Suppl 1): S15-8, 2000
95. Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ: An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. J Biol Chem 275(48): 37552-8, 2000